Skip to main content

Table 2 Univariate Cox proportional hazards analysis

From: Presence of HER4 associates with increased sensitivity to Herceptin™ in patients with metastatic breast cancer

 

Parameter

Overall survival

  

HR

95% CI

P

FISH

HER1

0.45

0.12 to 1.787

0.256

 

HER3

1.14

0.34 to 37.51

0.943

 

HER4

<0.01

<0.01 to 0.33

0.011

 

ERα

1.19

0.71 to 2.00

0.511

IHC

HER1

1.62

0.67 to 3.92

0.282

 

HER2 shedding

1.36

0.69 to 2.70

0.376

 

phospho-HER2

0.20

0.05 to 0.86

0.030

 

HER3

1.01

0.42 to 2.44

0.982

 

HER4

0.43

0.22 to 0.85

0.016

 

Ki-67

1.36

0.67 to 2.77

0.397

 

ER

1.00

0.92 to 1.08

0.979

 

PR

0.98

0.91 to 1.06

0.647

 

p27 Kip1

0.42

0.21 to 0.84

0.014

Others

Grading

2.01

0.83 to 4.87

0.123

 

Age (<50 vs. ≥ 50 years)

1.34

0.68 to 2.67

0.401

  1. Overall survival was defined from beginning of Herceptin™ treatment. Hazard ratios (HR), confidence intervals (CI) and P values of investigated parameters dependent on overall survival. CI with lower and upper limits. Data in bold define significant results.
  2. ER = oestrogen receptor; FISH = fluorescence in situ hybridisation; HER = human epidermal growth factor receptor; IHC = immunohistochemistry.